Related by context. All words. (Click for frequent words.) 71 MMP inhibitors 71 EGFR pathway 70 molecular biomarkers 70 anticancer therapies 69 mTOR inhibitors 69 BRAF inhibitors 68 antiangiogenesis 68 antiangiogenic agents 68 EGFR inhibitors 68 druggable targets 68 pharmacologic approaches 68 VEGF inhibitors 68 fibrotic disease 68 tyrosine kinase inhibitors 68 preclinically 68 chemopreventive agent 68 JAK inhibitors 68 molecular abnormalities 68 biomarker identification 68 Src inhibitors 67 histone deacetylase HDAC 67 immune modulating 67 multitargeted 67 ALK inhibitors 67 anti angiogenic agents 67 vascular disrupting agents 67 Symadex 67 kinase inhibition 67 molecularly targeted 67 XmAb# 67 PARP inhibitors 67 proteasome inhibitor 67 MEK inhibitors 67 deacetylase inhibitors 67 FTIs 67 HCV protease inhibitors 67 treating neuropathic pain 67 proteasome inhibitors 67 kidney urologic 67 CCR3 67 EGFr 67 antitumour 67 immune modulator 67 FGFs 67 antibody mediated 67 biologic therapeutics 66 SERMs 66 antitumor effect 66 HuLuc# 66 cytotoxic agents 66 CCX# 66 neuroprotectant 66 immunomodulation 66 CBLC# 66 immune modulatory 66 #ME# 66 antiangiogenic 66 bortezomib Velcade 66 synovial cells 66 antisense inhibitors 66 peptide antigens 66 antisense oligonucleotides 66 predictive biomarkers 66 TLR8 66 hedgehog pathway 66 anticancer therapy 66 investigational therapies 66 chemotherapeutic drugs 66 Anticalins R 66 tumor subtypes 66 Smac mimetic 66 mTOR inhibition 66 small molecule activators 66 neurotrophic 66 plasma kallikrein 65 biologic pathways 65 novel peptide 65 anti CD3 65 VDAs 65 Onconase 65 inhibit viral replication 65 angiogenesis inhibitor 65 radionuclide therapy 65 Spiegelmers R 65 PI3K inhibitors 65 neuro protective 65 cytostatic 65 Gleevec resistant 65 chemopreventive agents 65 MAPK pathway 65 Hedgehog inhibitor 65 VA# [002] 65 vivo potency 65 PARP inhibition 65 antiangiogenic drugs 65 vidofludimus 65 siRNA therapeutics 65 diagnostic biomarker 65 immunosuppressive regimens 65 myelofibrosis polycythemia vera 65 histone deacetylases 65 proliferative disorders 65 antimitotic 65 protein tyrosine phosphatases 65 histone deacetylase inhibitors 65 epithelial tumors 65 anti angiogenic therapies 65 selective inhibition 65 anticancer agents 65 immunosuppressive therapies 65 tyrosine kinase inhibitor 65 Anticalins 65 prognostic markers 65 potent inhibitors 65 therapeutic regimens 65 imatinib Gleevec 65 EGFR tyrosine kinase inhibitors 65 enzastaurin 65 Anticalins ® 65 sirtuin enzymes 65 pleiotropic 65 immunoregulatory 65 potent antiproliferative 65 ENMD # 65 Sphingomab 65 amyloid plaque formation 65 molecular determinants 65 cardiotoxic 65 epigenetic mechanisms 64 Azedra 64 hypoxic tumors 64 protein tyrosine phosphatase 1B 64 ALK inhibitor 64 tubulin inhibitor 64 HCV replication 64 CYT# potent vascular disrupting 64 thalidomide Thalomid 64 vitamin D analogs 64 fulvestrant 64 HbF 64 tumorigenicity 64 pharmacokinetic interactions 64 costimulatory 64 peptidic 64 pro angiogenic 64 Kinase inhibitors 64 inhibit angiogenesis 64 coagulation cascade 64 breast cancer metastasis 64 TNFa 64 enzyme inhibitors 64 LNP formulations 64 ESBA# 64 adeno associated viruses 64 immunotoxins 64 epigenetic therapies 64 SIRT1 activation 64 anti angiogenic therapy 64 antiangiogenic therapy 64 humanized monoclonal antibodies 64 endothelin antagonist 64 pre malignant lesions 64 TNFα 64 GIST tumors 64 cathepsins 64 KRAS oncogene 64 HDAC inhibitors 64 antiangiogenic agent 64 acadesine 64 immunomodulatory 64 Pseudomonas aeruginosa infections 64 metaglidasen 64 NF kB pathway 64 tumor metastases 64 ADME properties 64 SGLT2 inhibitors 64 protein kinase inhibitors 64 prostaglandin synthesis 64 therapeutic monoclonal antibody 64 GSK3B 64 thymidylate synthase TS 64 chemosensitivity 64 OMP #M# 64 imatinib resistance 64 cisplatin resistant 64 CB1 antagonists 64 PPARγ 64 inhibit EGFR 64 γ secretase 64 KRAS status 64 mitochondrial toxicity 64 chemoresistant 64 HDAC inhibition 64 MAGE A3 ASCI 64 cellular pathways 64 alkylating agent 64 telomerase inhibitor 64 erlotinib Tarceva 64 GRN# 64 flavopiridol 64 NKT cells 63 fusion enhancers 63 gefitinib Iressa 63 aneuploid cells 63 hematopoietic cells 63 biphosphonates 63 PROCHYMAL 63 IGF 1R 63 PHD2 63 rituximab Rituxan 63 antitumor immune 63 PI3K AKT 63 neuroinflammation 63 Squalamine 63 superficial bladder cancer 63 cancer immunotherapies 63 Smac mimetics 63 molecularly targeted therapies 63 nucleoside analogues 63 anticancer therapeutics 63 HER2 overexpression 63 Tyrima 63 LY# [003] 63 underlying molecular mechanisms 63 Beta catenin pathway 63 intracellular signaling pathways 63 sd rxRNA 63 choroidal neovascularization 63 inhibit metastasis 63 Anti VEGF 63 Zysolin TM 63 PDE4 inhibitors 63 mucosal immunity 63 anti fibrotic 63 p# inhibitors 63 Th2 cytokines 63 selective kinase inhibitors 63 panobinostat 63 dasatinib Sprycel 63 myeloproliferative diseases 63 genomic alterations 63 acetylcholinesterase AChE 63 anticancer treatments 63 antiplatelet therapies 63 DNA methylation patterns 63 antitumor efficacy 63 Sudhir Agrawal D.Phil 63 genomic biomarker 63 underlying pathophysiology 63 AEG# 63 antidiabetic drugs 63 chromosomal rearrangement 63 pharmacologic intervention 63 EGF receptor 63 Zevalin consolidation 63 AT1R 63 FGFR1 63 telomerase inhibition 63 UsiRNAs 63 neurite outgrowth 63 Angiolix 63 CXCR4 receptor 63 investigational monoclonal antibody 63 nucleoside analogs 63 delipidation 63 p# inhibitor 63 hedgehog signaling 63 cMET 63 riociguat 63 inhibiting tumor 63 HGS# 63 T#I [002] 63 FGFR 63 carbohydrate polymers 63 carcinoids 63 chemotherapeutic treatments 63 antiplatelet medications 63 Dasatinib 63 Wnt signaling pathway 63 investigational humanized monoclonal antibody 63 chemotherapeutic agents 63 microtubule targeting 63 tumor hypoxia 63 telomerase inhibitors 63 PDGF receptor 63 Treg cell 63 VEGF pathway 63 Nanobodies 63 Panzem 63 CCR9 antagonist 63 COX enzymes 63 lung metastasis 63 oral prodrug 63 vascular disrupting agent 63 pathogenetic 63 AChE inhibitors 63 cytoprotective 63 IDH mutations 63 tumor necrosis 63 TNF alpha antagonist 63 masitinib 63 diagnostic biomarkers 63 antithrombotic agents 63 endostatin 63 differentiated thyroid 63 OHR/AVR# 63 gamma secretase inhibitors 63 squamous cell lung cancer 63 Crizotinib 63 receptor tyrosine kinase inhibitor 63 chemopreventive 63 mGluR5 antagonist 63 thromboembolic disease 63 indolent lymphomas 63 echinocandins 63 angiogenesis inhibition 63 PI3K/mTOR 63 selectively inhibited 63 genetic aberrations 63 erythropoietic 63 interventional therapies 63 anticancer activity 63 humanised monoclonal antibody 63 MGd 63 antiproliferative effects 63 skeletal metastases 63 Factor Xa inhibitor 63 B7 H3 63 adipiplon 63 JAK2 inhibitors 63 aP2 62 CB2 receptor 62 selective modulator 62 systemically administered 62 OGG1 62 impair fertility 62 p# MAPK 62 HDACi 62 neuroprotective therapies 62 Temsirolimus 62 neuroinflammatory 62 insulin sensitizers 62 BRAF inhibitor 62 INS# [001] 62 IMA# 62 HepDirect prodrug 62 pharmacologic agents 62 PI3K Akt 62 relapsed ALL 62 virotherapy 62 #beta HSD1 62 VEGF receptor 62 potent anticancer 62 inhibiting mTOR 62 reperfusion injury 62 cediranib 62 LHRH antagonists 62 BCR ABL inhibitors 62 mimetics 62 gemcitabine Gemzar 62 immunostimulatory effects 62 immune modulation 62 anticancer agent 62 presymptomatic 62 neuropilin 62 miR #b [002] 62 FLT3 62 endogenous ligands 62 monoclonal antibody therapies 62 OXi# 62 anti mitotic 62 osteosarcomas 62 BRAF kinase 62 Hedgehog signaling pathway 62 CYP #A# 62 GRP# 62 metastatic RCC 62 gene amplification 62 lung fibrosis 62 MYCN amplification 62 chromosomal mutations 62 eTag assays 62 ISF# 62 iPS derived 62 oncomodulin 62 mutational status 62 protein kinase inhibitor 62 #beta HSD 1 62 pituitary adenomas 62 NSCLC tumors 62 macrolide antibiotics 62 AMPK activators 62 conventional chemotherapies 62 signaling cascades 62 stratifying patients 62 pharmacological approaches 62 Factor VIIa 62 thrombopoietin 62 cAMP signaling 62 antitumoral 62 antiarrhythmic 62 p# activation 62 florbetaben 62 activate p# 62 ACAT2 62 ixabepilone 62 PI3 kinase 62 TroVax ® 62 Rasagiline 62 iRGD 62 DACH platinum 62 Hepatocellular Carcinoma HCC 62 YONDELIS 62 murine models 62 WT1 62 Xanafide 62 beta adrenergic 62 pertuzumab 62 oncolytic viruses 62 thrombotic complications 62 Nanobodies ® 62 LRP5 62 somatic mutations 62 ADAMTS# 62 Therapeutic antibodies 62 Nanobody ® 62 receptor inhibitor 62 antifibrotic 62 sd rxRNA compounds 62 monoclonal antibody therapeutics 62 isotype 62 nanomedicines 62 bone morphogenetic proteins 62 EBV infection 62 immunomodulatory properties 62 antitumor 62 HER3 62 intracellular signal transduction 62 tumor antigens 62 anti angiogenic 62 renin inhibitors 62 Anavex #-# 62 PLX cells 62 cytotoxic therapies 62 enzyme inhibitor 62 hormone gastrin 62 microtubule inhibitor 62 Teriflunomide 62 IAP inhibitors 62 radiolabeled TM# 62 NEUGENE 62 IGF IR 62 uric acid lowering 62 act synergistically 62 CXCR7 62 A3 adenosine receptor 62 genetic determinants 62 Carfilzomib 62 biomarker assay 62 biologic therapy 62 GPCR targets 62 EP #R 62 antithrombotics 62 serotonin receptor 62 Protein Kinase C 62 MediGene focuses 62 Gefitinib 62 MEK ERK 62 small molecule defensin 62 antiviral therapies 62 micro RNAs 62 K ras mutations 62 Aplidin 62 lapatinib Tykerb 62 NTDDS 62 pathogenic mechanisms 62 Aviptadil 62 Cand5 62 druggable target 62 immuno modulatory 62 androgen receptor AR 62 GMX# 62 TLR9 agonist 62 visilizumab 62 NF kappaB activation 62 chemotherapeutic 62 immunomodulator 62 tumor vasculature 62 renal fibrosis 62 TLR antagonists 62 myelination disorders 62 Zolinza 62 resolvins 62 humanized antibody 62 Akt activation 62 infliximab Remicade 62 CA4P 62 anemias 62 glial tumors 62 mutated BRAF gene 62 gastrointestinal stromal tumors GISTs 62 anti CD# antibodies 62 chemotherapeutic agent 61 mAbs 61 Locked Nucleic Acid LNA 61 liposomal formulation 61 ErbB3 HER3 61 SERCA2a 61 REG1 61 Cytolin ® 61 metabolomic profiles 61 gastric carcinomas 61 motor neuron degeneration 61 haematopoietic 61 chimeric monoclonal antibody 61 Enzastaurin 61 TGF beta signaling 61 neuroprotective properties 61 immuno inflammatory 61 arterial calcification 61 RAF kinase 61 DHFR 61 metastatic melanomas 61 Immunosuppressive drugs 61 curative therapy 61 Oxidative damage 61 HSP# inhibitor 61 inhibit platelet function 61 TGF beta pathway 61 oxidative stress inducer 61 small molecule inhibitors 61 myelin repair 61 small molecule tyrosine 61 immunomodulators 61 microglial activation 61 Photodynamic therapy PDT 61 specific lectin receptors 61 hepatic toxicity 61 SIRT2 61 CMV infections 61 oncogenic signaling 61 necrotic core 61 USP# 61 breast cancer subtypes 61 metastatic neuroendocrine tumors 61 Xencor XmAb 61 VEGFb 61 malignant ascites 61 ependymomas 61 virulence genes 61 prostanoid 61 Camptothecin 61 DXL# 61 transgene expression 61 statins cholesterol lowering 61 intracellular pathways 61 systemic toxicity 61 Apatone 61 ATIR 61 AMN# [001] 61 Preclinical studies suggest 61 ischemic tissues 61 Deforolimus 61 rifamycins 61 VitiGam 61 ERK signaling 61 Hemopurifier TM 61 P#X# 61 alpha#beta# integrin 61 plasmid DNA vaccine 61 immunological diseases 61 HCV protease 61 Membrane proteins 61 amyloid deposition 61 immunotoxin 61 synthetic peptides 61 anti androgen 61 JAK3 61 Pertuzumab 61 TTR gene 61 neuroblastomas 61 IGFBP2 61 cathepsin K 61 basal cell carcinoma BCC 61 DFMO 61 siRNA therapeutic 61 oral JAK1 61 Trofex 61 undruggable 61 secretory pathway 61 endocrine therapies 61 beta interferons 61 Hedgehog signaling 61 TLE3 61 administered systemically 61 EGFR HER2 61 imexon 61 CDK inhibitors 61 PPARg 61 Notch1 61 untreated metastatic melanoma 61 Fc receptor 61 PXD# 61 cardiac repolarization 61 N Myc 61 RNAi therapeutic targeting 61 FGFR4 61 gene rearrangements 61 candida infections 61 #D#C# 61 monoclonal antibody mAb 61 post surgical adhesions 61 ZOLINZA 61 intravenous bisphosphonates 61 PLX# 61 mda 7 61 Intravenous CP 61 TMEM#B 61 chemotherapeutic drug 61 Hsp# inhibition 61 Htt 61 idarubicin 61 viral proteins 61 lipid lowering therapies 61 silico prediction 61 antiviral compounds 61 standard chemotherapy regimens 61 antimetastatic 61 inhaled anesthetics 61 somatostatin analogs 61 cytolytic 61 hepatic fibrosis 61 HER2 positive cancers 61 siRNA compounds 61 gamma secretase inhibitor 61 5 HT4 receptor 61 ImmunoVEX HSV2 61 adenosine receptor 61 Neuradiab 61 siRNA mediated 61 cetuximab Erbitux 61 calcineurin 61 GPR# agonists 61 EpCAM 61 oral anticoagulants 61 phosphate S1P 61 Bendavia 61 nucleosides 61 JAK2 inhibitor 61 naturally occurring antibodies 61 immune suppressive 61 mGlu2 3 61 trastuzumab Herceptin 61 intensive lipid lowering 61 PlGF 61 Adnectin 61 clade B 61 DNA gyrase 61 hepatotoxic 61 HDAC6 61 idraparinux 61 HGS ETR2 61 Aliskiren 61 EGFR HER 61 Amplimexon 61 recombinant erythropoietin 61 VEGF receptors 61 pyridostigmine 61 pDCs 61 CTLA4 Ig 61 OncoVEX 61 pancreatic adenocarcinoma 61 GSK3 61 antiapoptotic 61 factor IXa 61 mtDNA mutations 61 oral antiplatelet agent 61 pyrimidines 61 VAPRISOL 61 peripherally acting 61 noninfectious uveitis 61 TriRima 61 Interferon alpha 61 NF kB signaling 61 direct thrombin inhibitors 61 5 HT2B receptor 61 NRG1 61 PCA3 assay 61 peptibody 61 targeting PCSK9 61 oral Janus kinase 61 PRT# 61 BRAF mutation 61 antisense compounds 61 NS#/#A protease 61 sortilin 61 Wnt pathway 61 immunotherapeutic approaches 61 mecamylamine 61 factor Xa inhibitor 61 HER2 positive breast 61 NP2 Enkephalin 61 antiangiogenic activity 61 mGluR2 NAM 61 osteogenic 61 antiresorptive 61 Dapagliflozin 61 CaM kinase II 61 motesanib 61 myeloma cells 61 Alequel 61 DNA methyltransferases 61 Darapladib 61 Tß4 61 effector function 61 LHRH agonists 61 intracellular pathogens 61 uPA 61 indibulin 61 neovascular diseases 61 axonal regeneration 61 MDSCs 61 nanoviricide 61 ganetespib 61 Ets2 61 etiologic factors 61 protein misfolding 61 potentiator 61 dexpramipexole 61 mertansine 61 EGF receptors 61 percutaneous biopsy 61 opioid antagonists 61 PDE# inhibitors 61 methylation markers 61 M.tb 61 osteoclast activity 61 monoclonal antibody MAb 61 anti VEGF 61 miRNA expression 61 MUC1 * 61 leukotriene pathway 61 Hsp# inhibitors 61 epigenetic markers 61 anti CD3 antibody 61 Factor Xa inhibitors 61 taxane therapy 61 incretin 61 Exherin TM 61 pharmacologic 61 Bcr Abl mutations 61 adrenal suppression 61 KIT mutations 61 ERK pathway 61 prognostic biomarker 61 Cytolin R 61 allergic airway inflammation 61 urothelial bladder cancer 61 SSc 61 HER2 expression 61 histone modifications 61 colorectal liver metastases 61 erlotinib Tarceva ® 61 fibrocytes 61 Virulizin ® 61 TNF alpha inhibitor 61 cordycepin 61 taxol 61 bone morphogenetic proteins BMPs 61 targeted radiotherapeutic 61 kinase inhibitors 61 elacytarabine 61 antagomirs 61 inhibiting COX 61 glycopeptides 61 heparanase 61 platelet activation 61 demethylating agents 61 arterial thrombosis 61 melanoma tumors 60 vorinostat 60 histone deacetylase inhibitor 60 marketed EGFR 60 RKIP 60 neuroblastoma tumors 60 integrin receptors 60 anticoagulant warfarin 60 S. maltophilia 60 HDACs 60 serine proteases 60 enzymatic pathways 60 allogeneic HSCT 60 pharmacodynamic markers 60 radiosensitivity 60 mutant BRAF 60 Apo2L 60 Aggrastat ® tirofiban hydrochloride 60 antithrombotic 60 isoform selective 60 molecular underpinnings 60 CCR1 60 staphylococcal infections 60 epigenetic therapeutics 60 PDE4 inhibitor 60 stimulate neurogenesis 60 environmental toxicants 60 prognostic biomarkers 60 costimulation 60 mutated K ras 60 Lpathomab 60 PI3K delta 60 bone metastasis 60 Vidofludimus 60 nanocarriers 60 anti leukemic 60 allergic inflammation 60 NEUGENE antisense 60 polymerase inhibitors 60 BioSilicon 60 synthetic analogues 60 sorafenib Nexavar 60 #F FDG PET 60 antithrombotic therapy 60 canakinumab 60 factor Xa 60 PPAR gamma agonists 60 siRNA knockdown 60 apoptosis induced 60 immunological responses 60 PTP 1B 60 GPx 60 glutamate signaling 60 HepDirect technology 60 phosphatases 60 vemurafenib 60 mTOR signaling pathway 60 pharmacogenetic testing 60 renal toxicity 60 Affibody ® molecules 60 BRAF gene 60 monoclonals 60 GAP #B# 60 thymidylate synthase 60 neuropsychiatric diseases 60 HMGCR 60 immunosuppressive 60 lymphoid tumors 60 nicotinic acetylcholine receptor 60 retroviral vectors 60 polyketides 60 anthracycline chemotherapy 60 adrenal hormone 60 HIF 1α 60 intranasal delivery 60 trastuzumab DM1 60 immunopathology 60 metastatic tumor 60 RNAi therapeutic targeting PCSK9 60 STAT4 60 chemoprotective 60 non nucleoside 60 Tarvacin 60 unresectable tumors 60 tumor antigen 60 Panzem R NCD 60 Ceflatonin 60 novel anticancer 60 sarcosine 60 CD# antibody [001] 60 CCL# 60 tumor histology 60 intranasal corticosteroids 60 Hedgehog pathway 60 DCVax R 60 vivo validation 60 nodal metastasis 60 triphendiol 60 IgG1 antibody 60 liposomal doxorubicin 60 NKG2D 60 axonal degeneration 60 dissolving clots 60 Marqibo TM 60 pharmacological therapies 60 immune stimulatory 60 JAK inhibitor 60 NADPH oxidase 60 trastuzumab Herceptin ® 60 endocrine tumors 60 haematologic 60 pain palliation 60 monogenic 60 oral NSAIDs 60 topical retinoids 60 molecularly targeted therapy 60 thrombolytic agents 60 Prostatitis 60 IGFBP 3 60 histone deacetylase HDAC inhibitors 60 docetaxel Taxotere ® 60 metastatic lesions 60 tranilast 60 PPARgamma 60 c MET 60 mechanistic insights 60 therapies 60 HNSCC 60 primary cilia 60 ischemic preconditioning 60 TG# [003] 60 rBChE 60 lenalidomide dexamethasone 60 peptide inhibitors 60 miRNA molecules 60 4E BP1 60 surrogate endpoint 60 intravenous cyclophosphamide 60 cyclophilin D 60 diagnose Alzheimer disease 60 convenient dosing regimens 60 basal cell nevus syndrome 60 Degarelix 60 Cdc7 60 Revimmune 60 entinostat 60 mammary cancers 60 fibrate drugs 60 KRAS mutation 60 NS4A 60 induce apoptosis 60 TLR agonists 60 sirtuin activators 60 IAP inhibitor 60 atacicept 60 colon carcinoma 60 bleomycin 60 antiemetics 60 GPR# [002] 60 epothilones 60 recombinant antibodies 60 urothelial cancer 60 CaM kinase 60 Traficet EN 60 hormone refractory 60 EGFR antibodies 60 efaproxiral 60 cardiotoxic effects 60 blood clot dissolver 60 antimetabolites 60 corticosteroid dexamethasone 60 PI3K/Akt pathway inhibitor 60 dosage regimens 60 KL4 surfactant 60 Human cl 60 IKK2 60 HIF 1a 60 clefting 60 prostate carcinomas 60 pan HDAC inhibitor 60 cilengitide 60 selective inhibitors 60 Fibroblast Growth Factor Receptor 60 engineered RAP peptides 60 inhibit platelet aggregation 60 C5aR 60 immunomodulatory therapy 60 vascular disrupting 60 tyrosine kinase inhibitors TKIs 60 deforolimus 60 Inhaled corticosteroids 60 osteoclast 60 antitumor activity 60 validating biomarkers 60 cerebral vasospasm 60 eprotirome 60 splice variants 60 patient subpopulations 60 potent anti angiogenic 60 antiepileptics 60 GRK2 60 colorectal carcinogenesis 60 biodistribution 60 ImmuKnow 60 Vidaza azacitidine 60 mitochondrial fusion 60 Seliciclib 60 renal tumors 60 benfotiamine 60 Lixivaptan 60 PTHrP 60 NovaBay Aganocide compounds 60 NNR Therapeutics 60 regenerative therapy 60 TNF α 60 radiosensitive 60 leukaemic stem cells 60 humanized antibodies 60 Anthracycline 60 Erlotinib